SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

E Heilmann, F Costacurta, SA Moghadasi… - Science translational …, 2022 - science.org
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has …
被引用次数：71 相关文章
[HTML] nih.gov

[HTML][HTML] SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

E Heilmann, F Costacurta, SA Moghadasi, C Ye… - Science Translational … - ncbi.nlm.nih.gov
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor against the SARS-CoV-2 protease 3CL pro that has been licensed for …
[PDF] researchgate.net

[PDF][PDF] SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

E Heilmann, F Costacurta, SA Moghadasi, C Ye… - 2022 - researchgate.net
In late 2019, the zoonotic transmission of a new coronavirus, severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), into the human population (1), has led to worldwide …

SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

E Heilmann, F Costacurta… - Science …, 2023 - pubmed.ncbi.nlm.nih.gov
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CL pro that …

SARS-CoV-2 3CL pro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

E Heilmann, F Costacurta, SA Moghadasi, C Ye… - Science Translational … - akhw.at
@ article {CitekeyArticle, author='Baraldo, Giorgia; Etemad, Solmaz; Weiss, Alexander KH;
Jansen-Dürr, Pidder; Mack, Hildegard ID', title='Modulation of serotonin signaling by the …

SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

E Heilmann, F Costacurta… - Science …, 2023 - scholars.uthscsa.edu
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CL pro that …
[PDF] unipd.it

[PDF][PDF] SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

E Heilmann, M Pavan, D Bassani, A Volland… - TACKLING THE COVID … - research.unipd.it
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor against the SARS-CoV-2 protease 3CLpro that has been licensed for …

SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376.

E Heilmann, F Costacurta, SA Moghadasi… - Science Translational …, 2022 - europepmc.org
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor against the SARS-CoV-2 protease 3CL pro that has been licensed for …

SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376.

E Heilmann, F Costacurta… - Science …, 2023 - search.ebscohost.com
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CL< sup> pro …
[PDF] researchgate.net

[PDF][PDF] SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

E Heilmann, F Costacurta, SA Moghadasi, C Ye… - 2022 - researchgate.net
In late 2019, the zoonotic transmission of a new coronavirus, severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), into the human population (1), has led to worldwide …